DENVER, Colo. (247marketnews.com) -- Kodiak Sciences (NASDAQ:KOD), NeOnc Technologies Holdings (NASDAQ:NTHI), KNOREX (NYSEAMERICAN:KNRX), DataMeds AI (NASDAQ:MEDS), Accuray (NASDAQ:ARAY) and AMC Entertainment (NYSE:AMC) are each approaching important milestones that could reshape how investors view their pipelines, platforms and near-term prospects.
Kodiak Sciences: Retina Pipeline Hits Full Throttle
Kodiak Sciences (NASDAQ:KOD) delivered a major clinical catalyst as both Zenkuda and tabirafusp-ted met their primary vision endpoints in the Phase 3 DAYBREAK study in wet age-related macular degeneration. Zenkuda achieved non-inferiority versus aflibercept with a p-value of 0.0007, while 54% of patients reached a six-month dosing interval at one year under strict treat-to-dryness criteria. Kodiak also reported a 0% intraocular inflammation rate for Zenkuda in the trial.
The durability data could be particularly important in a retina market where reducing injection frequency remains a major treatment goal. Retina Consultants of America Chief Medical Officer David M. Brown called the DAYBREAK results “truly impressive,” saying more than half of patients were maintained on 24-week dosing through year one under stringent retreatment criteria.
Kodiak now plans a three-indication BLA submission for Zenkuda in the fourth quarter of 2026, covering wet AMD, diabetic retinopathy and retinal vein occlusion. Tabirafusp-ted, meanwhile, is advancing into the Phase 3 ALTO study in diabetic macular edema, while the company's third late-stage asset, KSI-101, remains on track for a December 2026 topline readout. CEO Victor Perlroth said the DAYBREAK results position the company for “the next stage of Kodiak's evolution.”
NeOnc Technologies Holdings: NEO212 Heads Toward Another FDA Test
NeOnc (NASDAQ:NTHI) continues building a multi-catalyst CNS cancer story around NEO212 and NEO100. NEO212 completed Phase 1 dose escalation, with 610 mg selected as the recommended Phase 2 dose, and the company has reported preliminary observations of prolonged disease control in heavily pretreated patients. NeOnc has emphasized that these observations are early clinical signals rather than proof of efficacy.
The program has also gained an international development path. In June, the Department of Health – Abu Dhabi granted IND status for NEO212, allowing the company to pursue Phase 2 development in the United Arab Emirates. Separately, the FDA has provided written feedback regarding NEO212's chemistry, manufacturing and controls program and its transition from capsule to tablet formulation.
The next major question is how the FDA discussions translate into the design of the next U.S. study. NeOnc has said it is seeking regulatory guidance on population, endpoints, dosing and a potential registrational strategy. CEO Amir Heshmatpour previously said the company is focused on “efficiently deploying capital” toward clinical milestones, while NEO100 provides a second potential development track for investors watching the company's CNS pipeline.
KNOREX: AI Moves from Chatbot to Advertising Execution
KNOREX (NYSEAMERICAN:KNRX) is pushing its advertising platform toward an increasingly AI-native model with KAI Assist and the planned KNOREX XPO MCP Server. KAI Assist introduces a conversational interface designed to let marketers create, launch and optimize cross-channel campaigns using natural-language commands instead of navigating multiple dashboard menus.
The company's planned October MCP Server launch takes that strategy further by connecting KNOREX XPO with external AI systems, including Anthropic's Claude and OpenAI models. The concept is to allow enterprise customers and agencies to query campaign performance, analyze cross-channel data and execute advertising changes through their preferred AI assistants.
“AI is truly the new UI,” said Abhishek Kumar, KNOREX's VP of Product and Engineering. The product push gives KNRX exposure to the rapidly developing agentic-AI advertising trend, but investors also have a separate corporate issue to monitor: KNOREX disclosed in August that it received an NYSE American notice concerning continued-listing standards. The company's AI rollout therefore arrives alongside an important exchange-compliance storyline.
DataMeds AI: Health Lives Here Expands Healthcare Platform
DataMeds AI (NASDAQ:MEDS) has launched the Health Lives Here mobile application with Tollo Health, initially targeting consumers using or considering GLP-1 therapies. The platform combines telehealth access, pharmacy services, nutritional products, wearable-data tracking and behavioral-health tools, while the companies plan to expand into Long COVID and eventually cancer-related services.
The application is being promoted through NFL Alumni Health and is tied to DataMeds' broader strategy of combining its EinsteinRx AI platform, PharmacyChain technology and Corexa pharmacy infrastructure. Gerald Commissiong, Interim Co-CEO of DataMeds AI, said, “Health Lives Here gives patients one front door to telehealth, their local pharmacist and their own health data.” The company says the initial pharmacy network is being built from Corexa's independent-pharmacy network, beginning with Moose Pharmacy of Concord in North Carolina.
The story is also expanding beyond the app itself. DataMeds completed its acquisition of Helomics' AI cancer-diagnostics laboratory and precision-oncology CRO businesses in September for a stated transaction value of $1.5 million, providing another potential component for its planned healthcare-data and cancer-management ecosystem. The company has also recently highlighted its September 28 presentation at the National Telehealth and Virtual Care Summit, where it plans to discuss patient control of health data and the Health Lives Here initiative.
Accuray: CyberKnife Gets Imaging Upgrade Story
Accuray (NASDAQ:ARAY) has entered into agreements with Samsung NeuroLogica to pursue advanced volumetric imaging capabilities for the CyberKnife platform. The collaboration combines Samsung NeuroLogica's mobile CT and volumetric-imaging expertise with Accuray's precision treatment delivery, robotic radiosurgery and motion-management capabilities.
The companies are exploring whether additional imaging information can be brought closer to treatment decision-making, potentially giving clinicians a more detailed view of anatomy during radiation treatment. The initiative is being highlighted at the American Society for Radiation Oncology annual meeting in Boston, putting the collaboration directly in front of the radiation-oncology community.
Accuray CEO Steve La Neve said the partnership reflects the company's strategy of deciding “where Accuray should lead, where we should collaborate, and how we translate customer priorities into action.” Importantly, no commercial product has been announced yet, and Accuray says development remains subject to technical, clinical and regulatory evaluation.
AMC Entertainment: Strong Box Office and New 52-Week High
AMC Entertainment (NYSE:AMC) is entering the fall with improving operating metrics and a major debt-refinancing effort underway. Preliminary figures for July and August showed North American box office of $2.46 billion, up 34.8% from the comparable period of 2025, while consolidated revenue reached $1.33 billion, a 42.2% increase. Attendance climbed 35.9% to 58.2 million patrons.
AMC set a new 52-week high of $3.32 today and, if volume remains strong, it could see a few more waves higher.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.